The company consists of three programs developing novel drugs in separate areas of inflammation. These programs are led by worldleading scientists at prestigious universities who have already developed blockbuster drugs and made ground-breaking discoveries in their fields.
One of the clinical programs is already conducting a phase 2b/3 trial and expects its first results in 2021. Further clinical trials are expected to begin by the end of 2020.
Professor Sir Marc Feldmann with his Lasker Award, European Inventor of the Year Award, and Gairdner Award
Professor Raphael Mechoulam receiving an honorary doctorate in Madrid
Professor Lawrence Steinman and Dr Jonathan Rothbard in Stanford University